{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:58:04Z","timestamp":1789757884556,"version":"4.0.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.clinthera.2015.05.501","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T20:15:28Z","timestamp":1434399328000},"page":"1564-1571","source":"Crossref","is-referenced-by-count":54,"title":["Susceptibility Profile of Ceftolozane\/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals"],"prefix":"10.1016","volume":"37","author":[{"given":"Christina A.","family":"Sutherland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.05.501_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.clinthera.2015.05.501_bib2","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"Infectious Diseases Society of America. 10 x 20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2015.05.501_bib3","series-title":"ZERBAXA (ceftolozane\/tazobactam) for injection, for intravenous use. Initial U.S. approval 2014","year":"2014"},{"key":"10.1016\/j.clinthera.2015.05.501_bib4","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/AAC.01737-10","article-title":"Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes","volume":"55","author":"Sader","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.05.501_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2011.02.004","article-title":"In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae","volume":"70","author":"Titelman","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2015.05.501_bib6","series-title":"CLSI document M07-A9","article-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2012"},{"key":"10.1016\/j.clinthera.2015.05.501_bib7","series-title":"CLSI document M100-S24 U","article-title":"2014. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement","year":"2014"},{"key":"10.1016\/j.clinthera.2015.05.501_bib8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/AAC.00912-09","article-title":"In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance","volume":"54","author":"Bulik","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.05.501_bib9","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1128\/AAC.01395-12","article-title":"Rapid identification of carbapenemase types in Enterobacteriaceae and Pseudomonas spp. by using a biochemical test","volume":"56","author":"Dortet","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.05.501_bib10","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2015.05.501_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14656566.2015.993381","article-title":"Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials","volume":"16","author":"Thabit","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2015.05.501_bib12","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1128\/AAC.01404-13","article-title":"In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012","volume":"57","author":"Walkty","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815008401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815008401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T19:53:25Z","timestamp":1537559605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815008401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0149291815008401"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.501","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}